- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05522660
Immunterapi eller målrettet terapi med eller uten stereootaktisk radiokirurgi for pasienter med hjernemetastaser fra melanom eller ikke-småcellet lungekreft (USZ-STRIKE)
En multisenter randomisert åpen fase III-studie av stereootaktisk radiokirurgi, i tillegg til standard systemisk terapi for pasienter med metastatisk melanom eller nylig diagnostisert metastatisk NSCLC og asymptomatiske eller oligosymptomatiske hjernemetastaser
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Heidi Roschitzki-Voser, Dr.
- Telefonnummer: +41 31 511 94 18
- E-post: heidi.roschitzki@etop.ibcsg.org
Studer Kontakt Backup
- Navn: Susanne Roux
- Telefonnummer: +41 31 511 94 17
- E-post: susanne.roux@etop.ibcsg.org
Studiesteder
-
-
-
Naples, Italia
- Rekruttering
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
-
Ta kontakt med:
- Paolo Ascierto
- E-post: p.ascierto@istitutotumori.na.it
-
Padova, Italia
- Har ikke rekruttert ennå
- Instituto Oncologico Veneto IRCCS
-
Ta kontakt med:
- Luisa Piccin
- E-post: luisa.piccin@iov.veneto.it
-
Perugia, Italia
- Rekruttering
- Santa Maria della Misericordia Hospital
-
Ta kontakt med:
- Mario Mandala
- E-post: mario.mandala@unipg.it
-
Roma, Italia
- Rekruttering
- Istituto Nazionale Tumori "Regina Elena"
-
Ta kontakt med:
- Gabriele Minuti
- E-post: gabriele.minuti@ifo.it
-
Rome, Italia
- Rekruttering
- Policlinico Umberto 1
-
Ta kontakt med:
- Giuseppe Minniti
- E-post: giuseppe.minniti@uniroma1.it
-
Siena, Italia
- Rekruttering
- Azienda ospedaliero-universitaria Senese Siena
-
Ta kontakt med:
- Anna Maria di Giacomo
- E-post: a.m.digiacomo@ao-siena.toscana.it
-
-
-
-
-
Amsterdam, Nederland
- Rekruttering
- NKI-AVL
-
Ta kontakt med:
- Paul Baas
- E-post: p.baas@nki.nl
-
-
-
-
-
Barcelona, Spania
- Rekruttering
- Vall Hebron Institute of Oncology (VHIO)
-
Ta kontakt med:
- Patricia Irano
- E-post: piranzo@vhio.net
-
Majadahonda, Spania
- Rekruttering
- Hospital Puerta de Hierro
-
Ta kontakt med:
- Ana Collazo Lorduy
- E-post: anaclorduy@gmail.com
-
Valencia, Spania
- Rekruttering
- Hospital La Fe
-
Ta kontakt med:
- Oscar Jose Juan Vidal
- E-post: juan_osc@gva.es
-
-
-
-
-
London, Storbritannia
- Rekruttering
- Royal Marsden (Sutton)
-
Ta kontakt med:
- Mary O'Brian
- E-post: mary.obrien@rmh.nhs.uk
-
Manchester, Storbritannia
- Rekruttering
- Christie NHS Manchester
-
Ta kontakt med:
- Sarah Hughes
- E-post: sarah.hughes91@nhs.net
-
-
-
-
-
Bern, Sveits
- Rekruttering
- Inselspital
-
Ta kontakt med:
- Ekin Ermis
- E-post: ekin.ermis@insel.ch
-
Winterthur, Sveits
- Rekruttering
- Kantonsspital Winterthur
-
Ta kontakt med:
- Natalie Fischer
- E-post: natalie.fischer@ksw.ch
-
Zurich, Sveits
- Rekruttering
- Universitätsspital Zürich
-
Ta kontakt med:
- Michael Weller, Prof.
- E-post: Michael.Weller@usz.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Most important inclusion criteria:
-
Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.
-
Requirements for brain metastases:
-
Brain metastases must be previously untreated, except for surgery.
-
Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.
-
Number and size of metastases at diagnosis of brain metastases:
- Maximum 1-10 brain metastases at screening
- At least one brain metastasis must be of ≥5 mm in diameter
- In case of 1-4 brain metastases:
- Longest diameter of largest brain metastasis must be ≤30 mm
- In case of 5-10 brain metastases:
- Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
- Maximum cumulative brain metastases volume must be ≤30 mL
-
Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC
-
Requirements for patients with melanoma:
-
Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).
-
BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).
-
Requirements for patients with NSCLC:
-
Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.
-
Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)
-
Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).
-
Age of 18 years or older
-
Karnofsky performance status of 60 or more
-
Life expectancy >12 weeks
-
Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).
-
Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.
-
Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Most important exclusion criteria:
- Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
- Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
- Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
- Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
- Prior whole brain irradiation or focal radiation therapy to the brain
- Prior systemic treatment for brain metastases
- Contra-indication for SRS
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Standard systemic treatment with stereotactic radiosurgery (SRS)
Arm A |
Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases. For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation. Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Andre navn:
|
|
Aktiv komparator: Standard systemic treatment without stereotactic radiosurgery
Arm B |
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CNS-specific PFS, locally assessed as per iRANO criteria
Tidsramme: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy. |
from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Michael Weller, MD, University of Zurich
- Studiestol: Rolf Stahel, MD, ETOP IBCSG Partners Foundation
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Hudsykdommer
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Nevroendokrine svulster
- Nevi og melanomer
- Neoplasmer i huden
- Hud- og bindevevssykdommer
- Karsinom, ikke-småcellet lunge
- Melanom
- Antineoplastiske midler, immunologiske
- Antineoplastiske midler
- Molekylære mekanismer for farmakologisk virkning
- Undersøkelsesteknikker
- Terapeutikk
- Kirurgiske prosedyrer, operativ
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Terapeutisk bruk
- Strålebehandling
- Stereotaksiske teknikker
- Nevrokirurgiske prosedyrer
- Immune Checkpoint-hemmere
- Radiokirurgi
Andre studie-ID-numre
- ETOP 19-21
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .